Document Type

Original Article


To assess the efficacy of Memantine as a preventive and therapeutic intervention for migraine and tension-type headache.

This clinical trial was conducted over a period of 3 months. A total of 44 subjects, with diagnosed migraine and/or tension-type headache, presenting to a private neurology clinic in Karachi, Pakistan were selected through purposive sampling technique. Patients were treated with incremental doses of Memantine. Adult patients belonging to both genders were included in the study. Data was analyzed using SPSS version 16.0 and associations were made using Chi square test with p-value of less than 0.05 taken as significant.

Out of 44 patients, 35 (79.5%) were females and 9 (20.5%) were males which shows a very high occurrence of migraine and tension-type headache in females. Average age was found to be 32.6 ≈ 33 years. Efficacy of the drug was observed to be 81.8% which is significantly high. The baseline MIDAS score when compared with the score at 3-month follow-up by applying Wilcoxon signed rank test showed mean ± S.D (39.52±21.27 vs. 6.72±6.41) where p=0.000 (<0.05) which shows a highly significant result. All 44 patients were known cases of migraine while 25% (11) of them also suffered from tension-type headache. Patients were treated with incremental doses of Memantine and were observed for the efficacy of the drug. Patients maintained their diaries of intensity of pain, distressing influence of the pain and how it hindered their daily routine. Results showed that intensity of pain decreased significantly by the end of the 3rd month of treatment and majority of the patients felt less distressed on their final follow-up visit. By the end of the 3rd month, the level of hindrance in the daily routines of the patients caused by the headache also fell significantly.

Memantine has significant beneficial effects in reducing intensity of pain and disability in patients with migraine and tension type headache.

Included in

Neurology Commons